Letter to the editor:
The primary ANA-positive (ANA+) idiopathic thrombocytopenia (ITP) is distinct from other primary ITPs due to its increased risk for devel- oping systemic autoimmune diseases, thrombosis, and refractoriness to first and second lines of ITP treatment.1,2 Evidence in treating pediatric patients with ANA+ ITP is limited as such reports are sporadic. A correct treatment of choice presents a challenge with several possible treatment options. We present the first pediatric patient success- fully treated with avatrombopag for ANA+ ITP without concomitant immunosuppressive therapy after the failure of steroids, eltrombopag, and romiplostim.
Pediatric Blood and Cancer- Volume71, Issue10, October 2024
DOI: 10.1002/pbc.31243
